GET DAILY SIGNALSWhy Is Arrowhead Pharmaceuticals (ARWR) Stock Down -13.53% Today?
Key Takeaways
- ARWR tumbled roughly 13.5% in Monday's session, sliding to about $50.29 from a prior close of $58.16.
- The primary catalyst was a combination of safety concerns from new cardiometabolic data and intensifying competitive pressure in the severe hypertriglyceridemia market.
- Secondary drivers included a technical breakdown below short-term moving averages that accelerated momentum-driven selling.
- The decline unfolded against a backdrop of elevated interest rates that continue to pressure long-duration biotech valuations.
- Traders are now watching Arrowhead's upcoming quarterly results, the regulatory path for plozasiran, and the commercial threat from Ionis Pharmaceuticals' competing therapy.
- For more detail on valuation, analyst views, and forward-looking estimates, explore Price Targets, Earnings, and Forecast pages.
- Looking for automated trading ideas? Browse Tickeron's Trending AI Robots to see the strongest-performing strategies under current market conditions.
Opening Summary
ARWR, Arrowhead Pharmaceuticals, Inc., is a Pasadena, California-based biopharmaceutical company that develops RNA interference (RNAi) therapies designed to silence disease-causing genes, with a pipeline concentrated in cardiometabolic, liver, and central nervous system diseases. In Monday's session, the shares plunged approximately 13.5%, trading near $50.29 versus a prior close of $58.16. The move extends a multi-session slide and reflects renewed investor concerns over the safety profile of its lead lipid-lowering programs and the competitive landscape for its flagship drug, plozasiran.
Safety Signals at the AHA Scientific Sessions
The heaviest selling pressure followed data presented at the American Heart Association Scientific Sessions in Chicago over the weekend. Arrowhead reported that its drug plozasiran reduced acute pancreatitis events by 78% versus placebo in a pooled analysis of the Phase 3 SHASTA-3 and SHASTA-4 studies, and by 91% in patients with a recent history of pancreatitis. While the efficacy readout was strong, investors zeroed in on tolerability: worsening glycemic control was reported in 14% of plozasiran-treated patients versus 8.7% on placebo, reinforcing existing scrutiny over blood-sugar effects for the drug class.
Separately, interim Phase 1/2a data for the company's dual-targeting investigational therapy ARO-DIMER-PA showed encouraging lipid reductions, including LDL cholesterol declines of up to 65%, but the safety profile drew attention. All 21 treated participants experienced an adverse event, most commonly injection-site reactions, and one patient experienced a serious fainting episode. These signals tempered enthusiasm that the pipeline would quickly de-risk.
Competitive Pressure From Ionis Pharmaceuticals
The selloff also reflects a shifting competitive dynamic. IONS, Ionis Pharmaceuticals, markets a directly competing APOC3-targeting therapy, olezarsen (Tryngolza), for severe hypertriglyceridemia. As Arrowhead works toward a supplemental approval for plozasiran in the broader severe hypertriglyceridemia population, the presence of an entrenched rival sharpens questions about long-term market share and pricing. Investors have responded by discounting the commercial upside that had previously supported ARWR's valuation.
Technical Breakdown and Broader Market Pressure
Beyond the fundamental catalysts, Monday's decline carried a heavy technical component. The stock broke decisively below short-term moving averages that had offered support in the $59–$60 range, triggering momentum and stop-loss selling as short-term technical indicators turned negative. The move was compounded by a broader environment in which elevated Treasury yields continue to weigh on unprofitable, long-duration biotech names that depend on future cash flows. ARWR has now fallen sharply over the past three months, and Monday's slide extended that downtrend rather than reversing it.
Market Context and Trading Activity
Trading in ARWR was notably active as sellers pressed the stock lower through the session, consistent with a high-beta, momentum-sensitive biotech name. The decline diverged from the comparatively stable performance of the broader healthcare sector, indicating that the move was company-specific rather than driven by sector-wide weakness. The stock traded well below its 52-week high and toward the lower end of its recent range, underscoring how far sentiment has cooled from earlier in the year.
What Comes Next for ARWR
Looking ahead, ARWR faces several near-term signposts. The company's next quarterly earnings report, expected in the coming weeks, will offer a read on plozasiran's commercial ramp and on operating-expense trends after a period of rising research spending and widening net losses. Investors will also monitor regulatory progress for plozasiran's supplemental filing in severe hypertriglyceridemia and any additional data clarifying the safety concerns raised at the AHA meeting. Competition from Ionis remains the central risk, while the company's broader RNAi platform and central nervous system pipeline represent potential offsets. For now, the burden is on management to reassure the market on both safety and commercial differentiation.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading strategies. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only those demonstrating the best results under current market conditions are featured in this section. The bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches that match their own objectives. If you are seeking data-driven trading ideas, consider exploring the Trending AI Robots to see what is currently outperforming.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
ARWR saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for ARWR moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 58 similar instances where the indicator exited the overbought zone. In 50 of the 58 cases the stock moved lower. This puts the odds of a downward move at 86%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 50-day moving average for ARWR moved below the 200-day moving average on October 27, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARWR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for ARWR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARWR's RSI Indicator exited the oversold zone, 18 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on ARWR as a result. In 70 of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for ARWR just turned positive on October 19, 2026. Looking at past instances where ARWR's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +2.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARWR advanced for three days, in 222 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
ARWR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating steady price growth. ARWR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.647) is normal, around the industry mean (3.498). P/E Ratio (-25.509) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (7.940) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (13.812) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARWR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of novel drugs to treat intractable diseases
Industry Biotechnology
Advertisement